Paradigm Biocapital Advisors
$4.9B Assets Reported
39 Holdings
Latest filing 2026-03-31
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ACLX | ARCELLX INC | 5,774,016 | $663M | 13.5% |
| RVMD | REVOLUTION MEDICINES INC | 6,655,703 | $647M | 13.2% |
| NUVL | NUVALENT INC | 5,324,433 | $545M | 11.1% |
| PCVX | VAXCYTE INC | 4,793,020 | $279M | 5.7% |
| EWTX | EDGEWISE THERAPEUTICS INC | 7,365,038 | $232M | 4.7% |
| GMAB | GENMAB A/S | 7,967,836 | $214M | 4.4% |
| INSM | INSMED INC | 1,254,488 | $205M | 4.2% |
| TARS | TARSUS PHARMACEUTICALS INC | 2,562,154 | $180M | 3.7% |
| BLTE | BELITE BIO INC | 1,114,784 | $178M | 3.6% |
| ERAS | ERASCA INC | 10,392,702 | $168M | 3.4% |
Track Paradigm Biocapital Advisors's 13F portfolio: $4.9B in reported holdings, 39 positions. Top holdings, AUM, and quarterly changes on SentiSense.